Importer of Controlled Substances; Notice of Application, 36482-36483 [E7-12954]
Download as PDF
<![CDATA[
36482
Federal Register / Vol. 72, No. 127 / Tuesday, July 3, 2007 / Notices
CFR 1301.34(b), (c), (d), (e) and (f) are
satisfied.
DEPARTMENT OF JUSTICE
Dated: June 26, 2007.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration.
[FR Doc. E7–12941 Filed 7–2–07; 8:45 am]
Drug Enforcement Administration
BILLING CODE 4410–09–P
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Manufacturer of Controlled
Substances; Notice of Application
Importer of Controlled Substances;
Notice of Application
Pursuant to Title 21 Code of Federal
Regulations 1301.34 (a), this is notice
that on February 2, 2007, Lipomed, Inc.,
One Broadway, Cambridge,
Massachusetts 02142, made application
by renewal to the Drug Enforcement
Administration (DEA) for registration as
an importer of the basic classes of
controlled substances listed in
schedules II:
Drug
Pursuant to § 1301.33(a) of Title 21 of
the Code of Federal Regulations (CFR),
this is notice that on March 13, 2007,
Johnson Matthey Inc., Custom
Pharmaceuticals Department, 2003
Nolte Drive, West Deptford, New Jersey
08066–1742, made application by letter
to the Drug Enforcement Administration
(DEA) to be registered as a bulk
manufacturer of the basic classes of
controlled substances listed in schedule
II:
Drug
Schedule
Cocaine (9041) .............................
Ecgonine (9180) ...........................
II
II
jlentini on PROD1PC65 with NOTICES
The company plans on producing
cocaine for sale to its customers, who
are final dosage manufacturers. The
ecgonine is formed during the
manufacturing process for cocaine.
Any other such applicant and any
person who is presently registered with
DEA to manufacture such a substance
may file comments or objections to the
issuance of the proposed registration
pursuant to 21 CFR 1301.33(a).
Any such written comments or
objections being sent via regular mail
should be addressed, in quintuplicate,
to the Drug Enforcement Administrator,
Office of Diversion Control, Federal
Register Representative (ODL),
Washington, DC 20537; or any being
sent via express mail should be sent to
Drug Enforcement Administration,
Federal Register Representative (ODL);
2401 Jefferson Davis Highway,
Alexandria, Virginia 22301; and must be
filed no later than September 4, 2007.
Dated: June 26, 2007.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration.
[FR Doc. E7–12947 Filed 7–2–07; 8:45 am]
BILLING CODE 4410–09–P
VerDate Aug<31>2005
17:57 Jul 02, 2007
Jkt 211001
Drug
Schedule
Cathinone (1235) ..........................
Methcathinone (1237) ..................
N-Ethylamphetamine (1475) ........
Methaqualone (2565) ...................
Gamma
Hydroxybutyric
Acid
(2010).
Lysergic acid diethylamide (7315)
2,5–Dimethoxy-4-(n)propylthiophenethylamine
(7348).
Marihuana (7360) .........................
Tetrahydrocannabinols (7370) .....
Mescaline (7381) ..........................
3,4,5–Trimethoxyamphetamine
(7390).
4–Bromo-2,5dimethoxyamphetamine (7391).
4–Bromo-2,5dimethoxyphenethylamine
(7392).
4–Methyl-2,5dimethoxyamphetamine (7395).
2,5–Dimethoxyamphetamine
(7396).
2,5–Dimethoxy-4ethylamphetamine (7399).
3,4–Methylenedioxyamphetamine
(7400).
3,4–Methylenedioxy-Nethylamphetamine (7404).
3,4–
Methylenedioxymethamphetamine (7405).
4–Methoxyamphetamine (7411) ...
Dimethyltryptamine (7435) ...........
Psilocybin (7437) ..........................
Psilocyn (7438) .............................
Acetyldihydrocodeine (9051) ........
Dihydromorphine (9145) ...............
Heroin (9200) ...............................
Normorphine (9313) .....................
Pholcodine (9314) ........................
Tilidine (9750) ...............................
Amphetamine (1100) ....................
Methamphetamine (1105) ............
Amobarbital (2125) .......................
Pentobarbital (2270) .....................
Secobarbital (2315) ......................
Phencyclidine (7471) ....................
Cocaine (9041) .............................
Codeine (9050) .............................
Dihydrocodeine (9120) .................
Oxycodone (9143) ........................
Hydromorphone (9150) ................
Benzoylecgonine (9180) ...............
PO 00000
Frm 00064
Fmt 4703
Sfmt 4703
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
II
II
II
II
II
II
II
II
II
II
II
II
Ethylmorphine (9190) ...................
Hydrocodone (9193) .....................
Levorphanol (9220) ......................
Meperidine (9230) ........................
Methadone (9250) ........................
Dextropropoxyphene, bulk (nondosage forms) (9273).
Morphine (9300) ...........................
Thebaine (9333) ...........................
Oxymorphone (9652) ...................
Alfentanil (9737) ...........................
Fentanyl (9801) ............................
Sufentanil (9740) ..........................
Schedule
II
II
II
II
II
II
II
II
II
II
II
II
The company plans to import
analytical reference standards for
distribution to its customers for research
and analytical purposes.
Any bulk manufacturer who is
presently, or is applying to be,
registered with DEA to manufacture
such basic classes of controlled
substances listed in schedule I or II,
which fall under the authority of section
1002(a)(2)(B) of the Act (21 U.S.C 952
(a)(2)(B) may file comments or
objections to the issuance of the
proposed registration and may, at the
same time, file a written request for a
hearing on such application pursuant to
21 CFR 1301.43 and in such form as
prescribed by 21 CFR 1316.47.
Any such comments or objections
being sent via regular mail should be
addressed, in quintuplicate, to the Drug
Enforcement Administration, Office of
Diversion Control, Federal Register
Representative (ODL), Washington, DC
20537; or any being sent via express
mail should be sent to Drug
Enforcement Administration, Office of
Diversion Control, Federal Register
Representative (ODL), 2401 Jefferson
Davis Highway, Alexandria, Virginia
22301; and must be filed no later than
August 2, 2007.
This procedure is to be conducted
simultaneously with and independent
of the procedures described in 21 CFR
1301.34(b), (c), (d), (e) and (f). As noted
in a previous notice published in the
Federal Register on September 23, 1975,
(40 FR 43745), all applicants for
registration to import a basic class of
any controlled substances in schedule I
or II are and will continue to be required
to demonstrate to the Deputy Assistant
Administrator, Office of Diversion
Control, Drug Enforcement
Administration, that the requirements
for such registration pursuant to 21
U.S.C 958(a); 21 U.S.C 823(a); and 21
CFR 1301.34(b), (c), (d), (e) and (f) are
satisfied.
E:\FR\FM\03JYN1.SGM
03JYN1
36483
Federal Register / Vol. 72, No. 127 / Tuesday, July 3, 2007 / Notices
Dated: June 26, 2007.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration.
[FR Doc. E7–12954 Filed 7–2–07; 8:45 am]
DEPARTMENT OF JUSTICE
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Drug Enforcement Administration
Manufacturer of Controlled
Substances; Notice of Application
Manufacturer of Controlled
Substances; Notice of Registration
BILLING CODE 4410–09–P
Pursuant to § 1301.33(a) of Title 21 of
the Code of Federal Regulations (CFR),
this is notice that on March 8, 2007,
Penick Corporation, 33 Industrial Road,
Pennsville, New Jersey 08070, made
application by renewal to the Drug
Enforcement Administration (DEA) to
be registered as a bulk manufacturer of
the basic classes of controlled
substances listed in schedule II:
By Notice dated March 19, 2007, and
published in the Federal Register on
March 27, 2007, (72 FR 14297), Roche
Diagnostics Operations, Inc., Attn:
Regulatory Compliance, 9115 Hague
Road, Indianapolis, Indiana 46250,
made application by renewal to the
Drug Enforcement Administration
(DEA) to be registered as a bulk
manufacturer of the basic classes of
controlled substances listed in schedule
I and II:
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Manufacturer of Controlled
Substances; Notice of Application
Pursuant to § 1301.33(a) of Title 21 of
the Code of Federal Regulations (CFR),
this is notice that on March 15, 2007,
Lonza Riverside, 900 River Road,
Conshohocken, Pennsylvania 19428,
made application by renewal to the
Drug Enforcement Administration
(DEA) to be registered as a bulk
manufacturer of the basic classes of
controlled substances listed in schedule
II:
Drug
Schedule
Drug
Schedule
Cocaine (9041) .............................
Codeine (9050) .............................
Dihydrocodeine (9120) .................
Oxycodone (9143) ........................
Hydromorphone (9150) ................
Diphenoxylate (9170) ...................
Ecgonine (9180) ...........................
Hydrocodone (9193) .....................
Morphine (9300) ...........................
Thebaine (9333) ...........................
Oxymorphone (9652) ...................
II
II
II
II
II
II
II
II
II
II
II
Drug
Lysergic Acid Diethylamide (7315)
Tetrahydrocannabinols (7370) .....
Alphamethadol (9605) ..................
Phencyclidine (7471) ....................
Ecgonine (9180) ...........................
Methadone (9250) ........................
Morphine (9300) ...........................
Schedule
I
I
I
II
II
II
II
The company plans to manufacture
bulk products for finished dosage units
and distribution to its customers.
Any other such applicant and any
person who is presently registered with
DEA to manufacture such a substance
may file comments or objections to the
issuance of the proposed registration
pursuant to 21 CFR 1301.33(a).
Any such written comments or
objections being sent via regular mail
should be addressed, in quintuplicate,
to the Drug Enforcement
Administration, Office of Diversion
Control, Federal Register Representative
(ODL), Washington, DC 20537, or any
being sent via express mail should be
sent to Drug Enforcement
Administration, Office of Diversion
Control, Federal Register Representative
(ODL), 2401 Jefferson Davis Highway,
Alexandria, Virginia 22301; and must be
filed no later than September 4, 2007.
The company plans to manufacture
the listed controlled substances as bulk
controlled substance intermediates for
distribution to its customers for further
manufacture or to manufacture
pharmaceutical dosage forms.
Any other such applicant and any
person who is presently registered with
DEA to manufacture such a substance
may file comments or objections to the
issuance of the proposed registration
pursuant to 21 CFR 1301.33(a).
Any such written comments or
objections being sent via regular mail
should be addressed, in quintuplicate,
to the Drug Enforcement
Administration, Office of Diversion
Control, Federal Register Representative
(ODL), Washington, DC 20537, or any
being sent via express mail should be
sent to Drug Enforcement
Administration, Office of Diversion
Control, Federal Register Representative
(ODL), 2401 Jefferson Davis Highway,
Alexandria, Virginia 22301; and must be
filed no later than September 4, 2007.
The company plans to manufacture
small quantities of the listed controlled
substances for use in diagnostic
products.
No comments or objections have been
received. DEA has considered the
factors in 21 U.S.C. 823(a) and
determined that the registration of
Roche Diagnostics Operations, Inc., to
manufacture the listed basic class of
controlled substance is consistent with
the public interest at this time. DEA has
investigated Roche Diagnostics
Operations, Inc., to ensure that the
company’s registration is consistent
with the public interest. The
investigation has included inspection
and testing of the company’s physical
security systems, verification of the
company’s compliance with state and
local laws, and a review of the
company’s background and history.
Therefore, pursuant to 21 U.S.C. 823,
and in accordance with 21 CFR 1301.33,
the above named company is granted
registration as a bulk manufacturer of
the basic class of controlled substance
listed.
Dated: June 26, 2007.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration.
[FR Doc. E7–12946 Filed 7–2–07; 8:45 am]
Dated: June 26, 2007.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration.
[FR Doc. E7–12945 Filed 7–2–07; 8:45 am]
Dated: June 26, 2007.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration.
[FR Doc. E7–12951 Filed 7–2–07; 8:45 am]
BILLING CODE 4410–09–P
BILLING CODE 4410–09–P
BILLING CODE 4410–09–P
jlentini on PROD1PC65 with NOTICES
Gamma
hydroxybutyric
acid
(2010).
Amphetamine (1100) ....................
Methylphenidate (1724) ................
VerDate Aug<31>2005
17:57 Jul 02, 2007
I
II
II
Jkt 211001
PO 00000
Frm 00065
Fmt 4703
Sfmt 4703
E:\FR\FM\03JYN1.SGM
03JYN1
]]>Agencies
[Federal Register Volume 72, Number 127 (Tuesday, July 3, 2007)]
[Notices]
[Pages 36482-36483]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: E7-12954]
-----------------------------------------------------------------------
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Importer of Controlled Substances; Notice of Application
Pursuant to Title 21 Code of Federal Regulations 1301.34 (a), this
is notice that on February 2, 2007, Lipomed, Inc., One Broadway,
Cambridge, Massachusetts 02142, made application by renewal to the Drug
Enforcement Administration (DEA) for registration as an importer of the
basic classes of controlled substances listed in schedules II:
------------------------------------------------------------------------
Drug Schedule
------------------------------------------------------------------------
Cathinone (1235)........................... I
Methcathinone (1237)....................... I
N-Ethylamphetamine (1475).................. I
Methaqualone (2565)........................ I
Gamma Hydroxybutyric Acid (2010)........... I
Lysergic acid diethylamide (7315).......... I
2,5-Dimethoxy-4-(n)- I
propylthiophenethylamine (7348).
Marihuana (7360)........................... I
Tetrahydrocannabinols (7370)............... I
Mescaline (7381)........................... I
3,4,5-Trimethoxyamphetamine (7390)......... I
4-Bromo-2,5-dimethoxyamphetamine (7391).... I
4-Bromo-2,5-dimethoxyphenethylamine (7392). I
4-Methyl-2,5-dimethoxyamphetamine (7395)... I
2,5-Dimethoxyamphetamine (7396)............ I
2,5-Dimethoxy-4-ethylamphetamine (7399).... I
3,4-Methylenedioxyamphetamine (7400)....... I
3,4-Methylenedioxy-N-ethylamphetamine I
(7404).
3,4-Methylenedioxymethamphetamine (7405)... I
4-Methoxyamphetamine (7411)................ I
Dimethyltryptamine (7435).................. I
Psilocybin (7437).......................... I
Psilocyn (7438)............................ I
Acetyldihydrocodeine (9051)................ I
Dihydromorphine (9145)..................... I
Heroin (9200).............................. I
Normorphine (9313)......................... I
Pholcodine (9314).......................... I
Tilidine (9750)............................ I
Amphetamine (1100)......................... II
Methamphetamine (1105)..................... II
Amobarbital (2125)......................... II
Pentobarbital (2270)....................... II
Secobarbital (2315)........................ II
Phencyclidine (7471)....................... II
Cocaine (9041)............................. II
Codeine (9050)............................. II
Dihydrocodeine (9120)...................... II
Oxycodone (9143)........................... II
Hydromorphone (9150)....................... II
Benzoylecgonine (9180)..................... II
Ethylmorphine (9190)....................... II
Hydrocodone (9193)......................... II
Levorphanol (9220)......................... II
Meperidine (9230).......................... II
Methadone (9250)........................... II
Dextropropoxyphene, bulk (non-dosage forms) II
(9273).
Morphine (9300)............................ II
Thebaine (9333)............................ II
Oxymorphone (9652)......................... II
Alfentanil (9737).......................... II
Fentanyl (9801)............................ II
Sufentanil (9740).......................... II
------------------------------------------------------------------------
The company plans to import analytical reference standards for
distribution to its customers for research and analytical purposes.
Any bulk manufacturer who is presently, or is applying to be,
registered with DEA to manufacture such basic classes of controlled
substances listed in schedule I or II, which fall under the authority
of section 1002(a)(2)(B) of the Act (21 U.S.C 952 (a)(2)(B) may file
comments or objections to the issuance of the proposed registration and
may, at the same time, file a written request for a hearing on such
application pursuant to 21 CFR 1301.43 and in such form as prescribed
by 21 CFR 1316.47.
Any such comments or objections being sent via regular mail should
be addressed, in quintuplicate, to the Drug Enforcement Administration,
Office of Diversion Control, Federal Register Representative (ODL),
Washington, DC 20537; or any being sent via express mail should be sent
to Drug Enforcement Administration, Office of Diversion Control,
Federal Register Representative (ODL), 2401 Jefferson Davis Highway,
Alexandria, Virginia 22301; and must be filed no later than August 2,
2007.
This procedure is to be conducted simultaneously with and
independent of the procedures described in 21 CFR 1301.34(b), (c), (d),
(e) and (f). As noted in a previous notice published in the Federal
Register on September 23, 1975, (40 FR 43745), all applicants for
registration to import a basic class of any controlled substances in
schedule I or II are and will continue to be required to demonstrate to
the Deputy Assistant Administrator, Office of Diversion Control, Drug
Enforcement Administration, that the requirements for such registration
pursuant to 21 U.S.C 958(a); 21 U.S.C 823(a); and 21 CFR 1301.34(b),
(c), (d), (e) and (f) are satisfied.
[[Page 36483]]
Dated: June 26, 2007.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of Diversion Control, Drug
Enforcement Administration.
[FR Doc. E7-12954 Filed 7-2-07; 8:45 am]
BILLING CODE 4410-09-P
